Clinical data released for zorevunersen, a gene‑regulation therapy for Dravet syndrome, showed dramatic seizure reductions and functional gains in pediatric patients. In open‑label cohorts reported by investigators at UCL and Great Ormond Street Hospital, treated children experienced 59%–91% fewer seizures and measurable quality‑of‑life improvements over up to 20 months. The trials, published in peer‑reviewed outlets, emphasize a mechanism that targets the disease’s SCN1A genetic cause rather than symptomatic control. Safety signals were described as mostly mild to moderate; a randomized Phase 3 trial is already under way to validate efficacy and support potential regulatory filings. If the phase‑3 program replicates these outcomes, the drug would represent a rare, disease‑modifying advance for a historically treatment‑resistant pediatric epilepsy.